Corrections

Request for slimming tablets

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2314 (Published 28 October 2008) Cite this as: BMJ 2008;337:a2314

In this 10-minute Consultation article the authors, S W Mercer and M E J Lean, referred to the use of rimonabant (BMJ 2008;337; a1287, doi:10.1136/bmj.a1287). However, since the article’s completion, the European Medicines Agency has announced that the drug’s benefits no longer outweigh its risks and has suspended its marketing authorisation across the European Union (www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf).

Notes

Cite this as: BMJ 2008;337:a2314

View Abstract